Chronic Myeloid Leukemia (CML)

  • ID: 3797437
  • Report
  • 208 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML.

Market Snapshot
  • The CML market will experience a short period of growth followed by a decline in sales due to the onset of generic competition.
  • The largest unmet needs in CML are overcoming TKI resistance and addressing patients with accelerated or blast phase disease.
  • The number of incident chronic myeloid leukemia cases is expected to increase by 25% over the next 20 years.
  • Generic imatinib will dominate first-line treatment as Sprycel and Tasigna compete for market share in the second line.
  • Asciminib is currently the primary candidate in the pipeline, and may benefit patients progressing on available TKIs.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: CHRONIC MYELOID LEUKEMIA (Published on 07 December 2017)
EXECUTIVE SUMMARY
MARKET OVERVIEW AND TRENDS
MARKET DEFINITION AND METHODOLOGY
ASCIMINIB
BOSULIF (BOSUTINIB)
GLEEVEC (IMATINIB)
ICLUSIG (PONATINIB)
SPRYCEL (DASATINIB)
SYNRIBO (OMACETAXINE MEPESUCCINATE)
TASIGNA (NILOTINIB)
PRIMARY RESEARCH METHODOLOGY

TREATMENT: CHRONIC MYELOID LEUKEMIA (Published on 08 November 2017)
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: CHRONIC MYELOID LEUKEMIA IN THE US, JAPAN, AND 5EU (Published on 08 November 2017)
EXECUTIVE SUMMARY
DISEASE BACKGROUND
SOURCES AND METHODOLOGY
FORECAST
EPIDEMIOLOGIST INSIGHT
STRENGTHS AND LIMITATIONS
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: CHRONIC MYELOID LEUKEMIA (Published on 07 December 2017)
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: BOSULIF
PRODUCT PROFILE: GLEEVEC
PRODUCT PROFILE: ICLUSIG
PRODUCT PROFILE: SPRYCEL
PRODUCT PROFILE: SYNRIBO
PRODUCT PROFILE: TASIGNA

PIPELINE: CHRONIC MYELOID LEUKEMIA (Published on 07 December 2017)
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
COMPARATOR THERAPY
PRODUCT PROFILE (LATE STAGE): ASCIMINIB

List of Figures
Figure 1: CML market value in the US, Japan, and five major EU markets, by country, 2016-25
Figure 2: Sales of tyrosine kinase inhibitors in CML, by brand, 2016-25
Figure 3: Proportion of drug-treated CML patients receiving branded versus generic products, 2016-25
Figure 4: Patient-based forecast methodology for CML
Figure 5: Price sources and calculations, by country
Figure 6: Asciminib sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
Figure 7: Bosulif sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
Figure 8: Gleevec sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
Figure 9: Iclusig sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
Figure 10: Sprycel sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
Figure 11: Synribo sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
Figure 12: Tasigna sales for CML in the US, Japan, and five major EU markets, by country, 2016-25
Figure 13: Distribution of prevalent CML cases according to phase, by country
Figure 14: Average proportion of CML patients receiving each treatment type, by phase and line of therapy
Figure 15: Top three first-line systemic therapy regimens for chronic-phase CML, by country
Figure 16: Top three second-line systemic therapy regimens for chronic-phase CML, by country
Figure 17: Top three third-line systemic therapy regimens for chronic-phase CML, by country
Figure 18: Top three first-line systemic therapy regimens for accelerated-phase CML, by country
Figure 19: Top three first-line systemic therapy regimens for blast-phase CML, by country
Figure 20: Proportion of CML patients receiving standard- or high-dose TKI therapy, by phase and line of therapy
Figure 21: Top three second-line systemic therapy regimens for accelerated-phase CML, by country
Figure 22: Top three second-line systemic therapy regimens for blast-phase CML, by country
Figure 23: Top three third-line systemic therapy regimens for accelerated-phase CML, by country
Figure 24: Top three third-line systemic therapy regimens for blast-phase CML, by country
Figure 25: Trends in incident cases of CML in the US, Japan, and five major EU markets, by country, 2016-36
Figure 26: Absolute change in incident cases of CML in the US, Japan, and five major EU markets, by country, 2016-36
Figure 27: Bosulif for CML - SWOT analysis
Figure 28: Drug assessment summary of Bosulif for CML
Figure 29: Drug assessment summary of Bosulif for CML
Figure 30: Gleevec for CML - SWOT analysis
Figure 31: Drug assessment summary of Gleevec for CML
Figure 32: Drug assessment summary of Gleevec for CML
Figure 33: Iclusig for CML - SWOT analysis
Figure 34: Drug assessment summary of Iclusig for CML
Figure 35: Drug assessment summary of Iclusig for CML
Figure 36: Sprycel for CML - SWOT analysis
Figure 37: Drug assessment summary of Sprycel for CML
Figure 38: Drug assessment summary of Sprycel for CML
Figure 39: Synribo for CML - SWOT analysis
Figure 40: Drug assessment summary of Synribo for CML
Figure 41: Drug assessment summary of Synribo for CML
Figure 42: Tasigna for CML - SWOT analysis
Figure 43: Drug assessment summary of Tasigna for CML
Figure 44: Drug assessment summary of Tasigna for CML
Figure 45: Asciminib for CML - SWOT analysis
Figure 46: Drug assessment summary of asciminib for CML
Figure 47: Drug assessment summary of asciminib for CML

List of Tables
Table 1: CML market value in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 2: Sales of tyrosine kinase inhibitors in CML, by brand ($m), 2016-25
Table 3: Summary of drug classes and molecules in the author’s CML forecast, 2016-25
Table 4: Exchange rates used for calculating prices
Table 5: Patent expiry dates for key marketed brands in CML in the US, Japan, and five major EU markets, by region, 2016-25
Table 6: Estimated launch dates of key pipeline products and marketed brands in CML in the US, Japan, and five major EU markets, by region, 2016-25
Table 7: Asciminib sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 8: Asciminib patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
Table 9: Bosulif sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 10: Bosulif patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
Table 11: Gleevec sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 12: Gleevec patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
Table 13: Iclusig sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 14: Iclusig patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
Table 15: Sprycel sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 16: Sprycel patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
Table 17: Synribo sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 18: Synribo patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
Table 19: Tasigna sales for CML in the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 20: Tasigna patient numbers for CML in the US, Japan, and five major EU markets, by country, 2016-25
Table 21: Hematologists and hematologist-oncologists surveyed for the CML primary research study, 2016
Table 22: Hematologists and hematologist-oncologists surveyed for the CML primary research study, 2016
Table 23: Commonly used prognostic systems in CML
Table 24: The author’s classification of CML by phase
Table 25: Leading brands for the treatment of CML
Table 26: CML phases defined by the WHO
Table 27: Cancer registry databases used as a source of CML incidence data, by country
Table 28: Forecasting methodology for CML incidence, by country, age group, and gender
Table 29: Incident cases of CML in the US, Japan, and five major EU markets, by country, 2016-36
Table 30: Age-specific incident cases of CML in the US, Japan, and five major EU markets, by country, 2016
Table 31: Gender-specific incident cases of CML in the US, Japan, and five major EU markets, by country, 2016
Table 32: Total incident cases of CML in the US, Japan, and five major EU markets by phase at diagnosis and country, 2016
Table 33: Validation of forecast estimates against benchmark estimates
Table 34: Key marketed drugs for CML
Table 35: Bosulif drug profile
Table 36: Bosulif pivotal trial data in CML
Table 37: Bosulif late-phase trial data in CML
Table 38: Gleevec drug profile
Table 39: Gleevec pivotal trial data in CML
Table 40: Gleevec late-phase trial data in CML
Table 41: Iclusig drug profile
Table 42: Iclusig pivotal trial data in CML
Table 43: Iclusig late-phase trial data in CML
Table 44: Iclusig ongoing late-phase clinical trials in CML
Table 45: Sprycel drug profile
Table 46: Sprycel pivotal trial data in CML
Table 47: Sprycel ongoing late-phase trial in CML
Table 48: Sprycel and Tasigna trial data in first-line CML
Table 49: Synribo drug profile
Table 50: Synribo pivotal trial data in CML
Table 51: Tasigna drug profile
Table 52: Tasigna pivotal trial data in CML
Table 53: Tasigna late-phase trial data in CML
Table 54: Phase III pipeline products in development for CML
Table 55: Survival rates, disease incidence, and drug development status of various hematologic cancers
Table 56: Gleevec drug profile
Table 57: Gleevec pivotal trial data in CML
Table 58: Asciminib drug profile
Table 59: Asciminib Phase III trial in CML
Table 60: Asciminib early-phase trial data in CML
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll